

#2/I.D.S.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JC511 U.S. PTO
09/503656
02/14/00

In Re: Application of) Art Unit:
William E. Baumzweiger and)
Kathleen L. Hannan)
Serial No.:) Examiner:
Filed:)
For: Brainstem and Limbic)
Disorder (BALD))

Commissioner Of Patents And Trademarks
Washington, DC, 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Prior to the filing of this application a patentability search was conducted. No prior art was found directly relative to this application in that this application covers a newly discovered medical syndrome diagnostic protocol and treatment protocol. However, of less relevance the below listed patents were located. Also extensive publications relative to this application are listed below.

US patent 4,599,340 filed July 8, 1986, discloses one use of calcium channel blocking drug usage in the context of soft tissue surgery. This is relevant to indicate the technology in the use of such drugs. However, the present application discloses an entirely new usage of such drugs.

US patent 5,250,414 filed October 5, 1993, discloses pharmacologic preparations that affect the brain and myelinated

1 neurons. This is remotely related to treatment of the BALD
2 syndrome disclosed in this application.

3 US patent 5,556,860 filed September 17, 1996 is relevant to
4 pyridine ring pharmacology and the use of such substances in
5 treatment of ischemic cerebral pathology. This illustrates the use
6 of pharmacologic preparations to treat calcium ion overload in
7 cells and is remotely relevant to this application.

8 US patent 5,671,741 filed September 30, 1997 is relevant to
9 the use of magnetic resonance imaging or MRI in the use of in vivo
10 diagnosis of necrotic tissue a technique use in the present
11 invention.

12 US patent 5,824,332 filed October 20, 1998, discloses a
13 surgical treatment for dysfunction of the brainstem and is remotely
14 relevant to this application which is not surgical.

15 US patent 5,846,977 filed December 08, 1998, discloses a
16 method of treatment of functional disorders of the central nervous
17 system using quinoline/quinone preparations and is remotely related
18 to the present invention.

19 US patent 5,851,783 filed December 22, 1998 discloses a method
20 of diagnosis of a related disorder of the brain amyotrophic lateral
21 sclerosis using immunoassay procedures. This is remotely related
22 to the present diagnosis and treatment protocol of the BALD
23 syndrome.

24 US patent 5,861,290 filed January 19, 1999 discloses treatment
25 of viral infection which is one step in the treatment protocol of
26 the present invention. This patent illustrates the use of
27 pharmaceutical preparations such as acyclovir a preparation used in
28 the present invention and is remotely related to this application.

1 US patent 5,885,998 filed March 23, 1999, discloses methods of
2 treatment of central nervous system dysfunction with pharmacologic
3 compounds related to pyridine chemistry and is remotely related to
4 the present invention.

5 US patent 5,902,609 filed May 11, 1999 relates to controlling
6 wound scar production using a calcium antagonist and remotely is
7 related to the present application.

8 The article Cot Death (SIDS) pages 14-15 published in Nexus
9 Magazine October-November 1999 discusses how crib death is related
10 to toxic substances which is an aspect of the present invention.

11 The publication Brainstem Examination for Patients Suffering
12 From Gulf War Syndrome and Other Brainstem Dysregulations by
13 William E. Baumzqwier, MD, of July 4, 1996 is related to early
14 work in the reduction to practice of the present invention.

15 The publication Treatment Protocol For Neurotoxicity Copyright
16 1998 by William E Baumzweiger, MD, also relates to early work in
17 the reduction to practice of the present invention.

18 The publication Brainstem-Limbic Immune Dysregulation in Ill
19 Gulf War Veterans International Journal Of Medicine Volume 1, Issue
20 3, pages 136-150, Winter 1998, Aeolian Press La Jolla California
21 discusses early work in reduction to practice of the present
22 invention.

23 The publication Neuro-Immuno-Reinfection And Its Clinical
24 Consequences in Diseases published at the CDC Conference in Atlanta
25 Georgia February 28-March 2, 1999 by William E Baumzweiger, MD and
26 Aristo Vojdani, PhD Copyright 1999 is also relevant to prior work
27 in the reduction to practice of the present invention.

28 The publication Protocol For The Treatment Of Moderate

1 Relapses Of Symptoms From Neurotoxic Syndrome July 1999 also
2 relates to early work in the reduction to practice of the present
3 invention.

4 The publication Background Information Related to Brainstem,
5 Basal Ganglia, Limbic Disorder July, 1999 also relates to early
6 work in the reduction to practice of the present invention.

7 The Copyrighted publication Confidential Background
8 Information For Patent Application July 1999 by William E
9 Baumzweiger, MD also relates to early work in the reduction to
10 practice of the present invention.

11 The publication Definition Of Brainstem, Basal Ganglia And
12 Limbic Disorder (BALD) of July , 1999, by William E Baumzweiger,
13 MD, also is related to earlier work in the reduction to practice of
14 the present invention.

15 The publication Pathophysiology, Third Edition, McGraw-Hill,
16 Copyright 1986 pages 752 to 760 relates to examination of the
17 twelve cranial nerves, clinical examination of motor function, and
18 examination of reflexes which methods are used in the present
19 invention.

20 The publication Drug Facts And Comparisons, 1999 Edition,
21 Facts and Comparisons™ relates to the pharmacology of the treatment
22 protocol of the present invention. The present invention discloses
23 new uses for many of these preparations. However, the prior art
24 related to this invention is clearly relevant. The relevant pages
25 are listed below.

26 Pages 341 to 346 are related to the anticoagulant Heparin.

27 Pages 530 to 533 are related to Growth Hormone.

28 Page 590 is related to the glucocorticoid Methylprednisolone.

Pages 872 to 873 is related to calcium channel blocking agents
nimotop and plendil.

Pages 1073 to 1074 are related to edetate disodium.

Pages 1146 to 1148 related to the leukotriene receptor antagonist Zafirlukast also known as Accolate.

Pages 1153 to 1156 related to the leukotriene receptor inhibitor Singulair.

Page 1517 relates to Azulfidine.

Page 1219 relates to the antihistamine Benadryl.

Page 1383 relates to Morphine Sulfate.

Pages 1633 to 1635 relates to the antidepressant Trazodone Hydrochloride.

Page 1848 relates to Clonazepan.

Pages 1895 to 1900 relates to the anticonvulsant Gabatril.

Pages 2009 to 2010 relates to Amantadine Hydrochloride.

Page 2036 relates to Maxox.

Pages 2435 to 2446 relate to the antifungal agents Fluconazole and Sporanox.

Pages 2516 to 2519 relate to Valtrex and antiviral agents.

Pages 2585 to 2590 relate to Acyclovir as an antiviral agent.

Pages 2694 to 2698 relate to immune serums and Immune Globulin, IV.

It is believed that any other references would either have extremely remote relevance to the present invention or would be cumulative.

/

/

1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Respectfully submitted.

February 8, 2000

LAW OFFICE OF NATHAN BOATNER



Nathan Boatner, Attorney
Reg. No. 32856
PMB 692, 7095 Hollywood Blvd,
Los Angeles, CA, 90028
(213) 840-8286